INTRODUCTION
============

In patients with chronic kidney disease (CKD) not on dialysis, therapy for anemia with recombinant human erythropoietin (rhEPO) and its analogs is often reserved for those with more advanced CKD \[[@sfy013-B1]\]. Several large randomized trials \[e.g. The Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial, \[[@sfy013-B2]\] The Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial \[[@sfy013-B3]\] and Trial to Reduce Cardiovascular Events with Aranesp Therapy (Treat) trial \[[@sfy013-B4]\]\] have reported adverse cardiovascular outcomes and death when using rhEPO and its analogs to target hemoglobin levels \>13 g/dL, which led the US Food and Drug Administration to revise the safety language in labeling for rhEPO and its analogs in 2007 \[[@sfy013-B5]\] and again in 2011 \[[@sfy013-B6]\]. These changes included limiting treatment initiation in CKD patients not on dialysis to when the hemoglobin level is \<10 g/dL, and reducing or interrupting the dose of rhEPO if the hemoglobin level is \>10 g/dL \[[@sfy013-B5]\].

To improve treatment options over existing marketed rhEPO and its analogs, new investigational agents including hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitors (PHIs), such as daprodustat, are being developed \[[@sfy013-B8]\]. The mechanism of action of these agents is described in detail elsewhere \[[@sfy013-B14]\]. Briefly, PHIs act by inhibiting HIF-prolyl hydroxylase enzymes (PHD1, PHD2 and PHD3), leading to activation of HIF-responsive genes that regulate the tissue response to hypoxia. One key activity is induction of erythropoiesis through direct activation of the *EPO* gene. In addition, HIF activation results in the induction of a number of genes directly or indirectly involved in iron uptake, mobilization and transport, resulting in decreased hepcidin production, as well as vascular endothelial growth factor (VEGF) \[[@sfy013-B14]\]. Potential advantages of daprodustat and other PHIs over rhEPO and its analogs in the treatment of anemia of CKD include: (i) raising hemoglobin without exposing the patient to the supraphysiologic EPO levels and increases in blood pressure (BP) associated with intravenous (IV) rhEPO and its analogs; (ii) improving iron availability for erythropoiesis, which may reduce the need for iron replacement therapy; and (iii) avoiding the need for parenteral injection.

The dose response for daprodustat was previously defined in rhEPO-naïve patients with CKD \[[@sfy013-B10]\]. Here, we report the results of a 24-week clinical trial that assessed the ability of daprodustat to achieve and maintain hemoglobin levels within a prespecified target range in patients with CKD Stages 3, 4 or 5, both as an initiation therapy in rhEPO-naïve participants and as a switch therapy for participants already receiving rhEPO.

MATERIALS AND METHODS
=====================

Study population
----------------

Informed consent was obtained from all participants. Eligible participants had CKD Stages 3, 4 or 5 as defined by the Japanese Society of Nephrology-Chronic Kidney Disease Initiatives equation \[[@sfy013-B15]\] for Japanese participants residing in Japan and the CKD-Epidemiology Collaboration equation \[[@sfy013-B16]\] for Caucasian and African-American populations. Participants who were rhEPO naïve were not to have used rhEPO within 8 weeks before screening; those who were rhEPO users were required to be on stable doses of the same rhEPO for the 4 weeks before entering the trial. Inclusion and exclusion criteria, and predefined study medication stopping criteria can be found in the [Supplementary data, Item S1](#sup1){ref-type="supplementary-material"}.

Study design
------------

This global study (ClinicalTrials.gov identifier NCT01977573) was conducted from 17 December 2013 to 19 June 2015 at 84 sites in 15 countries in adherence with the Declaration of Helsinki, and was approved by the relevant institutional review boards or ethics committees. An internal GlaxoSmithKline Safety Review Team reviewed blinded safety data instream and an independent data monitoring committee periodically reviewed the same safety data, but it was unblinded.

The study consisted of a 4-week screening phase, a 24-week treatment phase and a follow-up visit ∼4 weeks after completing treatment. Participants who discontinued study medication or withdrew early from the study attended an early withdrawal (EW) visit, an EW follow-up visit 4 weeks later, phone assessments aligned with the remaining key study visits and an EW final visit at Week 24. Study investigators or staff were responsible for monitoring and recording adverse events (AEs). AEs were collected from the start of study treatment and until the follow-up contact. (Additional information on the study design and study assessments performed, including laboratory assessments, safety reporting, echocardiology and ophthalmology examinations, is included in the [Supplementary data, Item S2](#sup1){ref-type="supplementary-material"}; the study design is shown in [Supplementary data, Figure S1](#sup1){ref-type="supplementary-material"}.)

Participants were assigned to one of two groups based on previous exposure to rhEPO: those who were currently receiving rhEPO (rhEPO users) and those who were not (rhEPO naïve). Hemoglobin entry criteria and target values were modified during the study to more closely align with anemia guidelines and clinical practices outside the USA ([Table 1](#sfy013-T1){ref-type="table"}). Separate randomization lists were generated for the two groups (rhEPO naïve and rhEPO users) by a GlaxoSmithKline statistician using the GlaxoSmithKline randomization system RandAll. The stratification variables (region and baseline hemoglobin range; [Supplementary data, Table S1 in Item S2](#sup1){ref-type="supplementary-material"}) were used as blocking factors. Block size of four was used. Participants were assigned a randomization number by an interactive voice/web response system. Participants who were rhEPO naïve were randomized 3:1 to once-daily daprodustat (1, 2 or 4 mg daily depending on baseline hemoglobin) or control, and rhEPO users were randomized 1:1 to daprodustat 2 mg daily or control. Starting doses of daprodustat were based on dose-response modeling from previous studies. Control participants received rhEPO (epoetins or their biosimilars or darbepoetin) as necessary per standard of care as determined by the investigator. Because of the different routes of administration, rhEPO dosing data were standardized in terms of epoetin IV dosing (reported in IU/kg/week) (see [Supplementary data, Item S2](#sup1){ref-type="supplementary-material"}). Table 1.Hemoglobin entry criteriaCohort 1[^a^](#tblfn2){ref-type="table-fn"}Cohort 2 (ex-USA)Hemoglobin entryHemoglobin target rangeHemoglobin entryHemoglobin target rangerhEPO-naïve participants8--10 g/dL9--10.5 g/L8--11 g/dL10--11.5 g/dLrhEPO users9--10.5 g/dL9--10.5 g/dL9--11.5 g/dL10--11.5 g/dL[^1][^2]

The dose of daprodustat was kept constant for the first 4 weeks, after which the dose could be adjusted based on a prespecified dose adjustment algorithm to achieve and/or maintain hemoglobin within the target range. Dose adjustments were made automatically by the interactive voice/web response system so the participant, investigator, site staff and study team were blinded to the dose being administered during the study. Those in the control group could receive rhEPO therapy, with doses adjusted as determined by the investigator with the intention of treating to the same hemoglobin target range as the daprodustat group. To ensure participants remained iron replete throughout the study, an iron protocol was instituted from Week 4 onwards ([Supplementary data, Table S2 in Item S3](#sup1){ref-type="supplementary-material"}). The complete study objectives and endpoints can be found in [Table 2](#sfy013-T2){ref-type="table"}. Table 2.Study objectives and endpointsObjectivesEndpointsPrimaryCharacterize the ability of daprodustat to achieve mean hemoglobin response within the target rangeHemoglobin concentration at Week 24SecondaryCharacterize the ability of daprodustat to achieve hemoglobin within the target rangePercentage of time within, below and above target range, between Weeks 12 and 24Number (%) of participants with hemoglobin in the target range at Week 24Number (%) of participants reaching predefined hemoglobin stopping criteriaCharacterize the effect of daprodustat on measures of iron metabolism and utilization, on indices of hematopoiesis, EPO and on VEGFChange from baseline in hepcidin, ferritin, transferrin, TSAT, total iron, TIBC and CHr at Week 24Change from baseline in hematocrit and RBCsRBCs, reticulocyte number at Week 24Maximum observed change from baseline in EPOMaximum observed change from baseline in VEGFCharacterize the steady-state population PK of daprodustat and metabolitesPopulation plasma PK parameters of daprodustat and metabolitesEvaluate the daprodustat dose adjustment schemeNumber, frequency and timing of dose adjustmentsTotal cumulative and final doseNumber of hemoglobin excursions, hemoglobin cycles and dose cyclesNumber (%) of participants with at least one hemoglobin excursionNumber (%) of participants with at least one hemoglobin cycleNumber (%) of participants with at least one dose cycleTime that dose is held because hemoglobin exceeded the upper limitNumber (%) of participants receiving additional therapies of blood transfusions, IV iron or rhEPOSafetyAssess the safety and tolerability of daprodustatIncidence and severity of AEs and SAEs as reasons for discontinuation of study treatment, including discontinuation for safety-related reasons (e.g. prespecified stopping criteria or AE), absolute values and changes from baseline in laboratory parameters, estimated sPAP, LVEF, ophthalmology assessments and vital signsPreliminary assessment of MACE (defined as all-cause mortality, myocardial infarction or stroke) and other CV events[^3]

Statistical analyses
--------------------

The planned sample size for this study was driven by exposure requirements to achieve ∼100 evaluable participants treated with daprodustat, where a participant was considered evaluable if they had on-treatment data at Week 24. (See [Supplementary data, Item S4](#sup1){ref-type="supplementary-material"} for additional justification.)

The intent-to-treat (ITT) population in the daprodustat groups comprised all randomized participants who received at least one dose of study treatment and had a baseline and at least one postbaseline on-therapy hemoglobin assessment. For the control groups, the ITT population comprised all randomized participants who had a baseline and at least one postbaseline on-therapy hemoglobin assessment. The safety population in the daprodustat groups comprised all participants who received at least one dose of study treatment, whereas it comprised all randomized participants in the control groups.

For the primary analysis, mean hemoglobin concentration at Week 24 was measured and corresponding 95% confidence intervals were calculated. As part of the secondary analysis, percentage of time hemoglobin values were within, above and below the target range between Weeks 12 and 24 (inclusive) was also calculated. Efficacy endpoints were summarized in the ITT population for each rhEPO group (naïve and user) and the two treatment groups (daprodustat and control) using summary statistics. In particular, hemoglobin was summarized by rhEPO group, the two cohorts (based on hemoglobin entry criteria) and treatment group. The data for the control groups served as a reference only; no formal comparisons with daprodustat were made.

RESULTS
=======

Study population
----------------

Two hundred fifty-two participants were randomized to either daprodustat (*n* = 172) or control (*n* = 80) ([Figure 1](#sfy013-F1){ref-type="fig"}). Of those randomized, 250 (\>99%) were included in the safety population and 235 (93%) in the ITT population, with 222 (88%) completing the study (i.e. participants who completed the Week 24 visit regardless of whether they remained on study treatment) \[148 (86%) in the daprodustat group and 74 (93%) in the control group\].

![Study flow diagram. ^a^One participant withdrew from the study because of an AE; however, this participant's AE was actually a protocol-defined stopping criterion and is presented here in the stopping criteria category rather than the AE category. ^b^Completed all study visits or abbreviated schedule if study medication was discontinued. ^c^Fifteen participants discontinued study medication because of AEs; however, five of these participants had AEs that were actually protocol-defined stopping criteria and are presented here in the stopping criteria category rather than the AE category. ^d^One participant discontinued study medication because of an AE; however, this participant's AE was actually a protocol-defined stopping criterion and is presented here in the stopping criteria category rather than the AE category. ^e^Protocol-defined reasons for discontinuation of study medication included hemoglobin \<7.5 g/dL, renal transplant, increased sPAP of ≥20 mmHg, drop of LVEF ≥10% from baseline and \<50% and blood transfusion. The complete list of stopping criteria is included in [Supplementary data, Item S1](#sup1){ref-type="supplementary-material"}. IP: investigational product; PI: principal investigator.](sfy013f1){#sfy013-F1}

The most common reasons for premature withdrawal were an AE in the daprodustat group (5%) and withdrawal by participant in the control group (3%).

Similar proportions of participants (20% randomized to daprodustat; 18% randomized to control) discontinued study treatment prematurely. The most common reasons for treatment discontinuation were an AE in the daprodustat group (10%) and reaching the protocol-defined stopping criteria in the control group (8%) \[included renal transplant, increased systolic pulmonary artery pressure (sPAP) of ≥20 mmHg, drop of left ventricular ejection fraction (LVEF) ≥10% from baseline and \<50% and blood transfusion\]. Participants that finished the entire treatment as well as those with an abbreviated treatment schedule were included in the ITT population.

Overall, baseline characteristics were well balanced between the combined daprodustat and control groups. The majority of participants were female (59%), with a mean body mass index (BMI) of 27.8 kg/m^2^ and mean age of 66.1 years ([Table 3](#sfy013-T3){ref-type="table"}). Mean baseline hemoglobin was 10.0 g/dL and most participants had Stage 4 (46%) or Stage 5 (36%) CKD. Table 3.Participant characteristics (ITT population)rhEPO naïverhEPO userTotalDaprodustatControlDaprodustatControlDaprodustatControl(*n* = 123)(*n* = 43)(*n* = 33)(*n* = 36)(*n* = 156)(*n* = 79)Age, years, mean (SD)67.6 (12.21)64.3 (14.22)62.0 (14.06)66.7 (12.89)66.5 (12.78)65.4 (13.6)Sex, female, *n* (%)75 (61)23 (53)17 (52)23 (64)92 (59)46 (58)Weight (kg), mean (SD)73.2 (19.64)77.1 (16.03)77.1 (23.49)71.7 (18.60)74.1 (20.49)74.6 (17.35)BMI (kg/m^2^), mean (SD)27.7 (6.9)28.4 (5.4)28.1 (7.1)27.3 (6.4)27.8 (6.9)27.9 (5.9)Hemoglobin criteria[^a^](#tblfn5){ref-type="table-fn"}*n* (%) Cohort 152 (42)18 (42)21 (64)17 (47)73 (47)35 (44) Cohort 277 (58)25 (58)12 (36)19 (53)83 (53)44 (56)Baseline hemoglobin level (g/dL), mean (SD)[^b^](#tblfn6){ref-type="table-fn"}9.9 (0.80)9.9 (0.73)10.2 (0.62)10.2 (0.57)10.0 (0.77)10.1 (0.67)Type of rhEPO, *n* (%) Epoetin SC0014 (42)5 (14)14 (42)5 (14) Darbepoetin0019 (58)30 (86)19 (58)30 (86)Geographical region, *n* (%) Japan17 (14)6 (14)9 (27)9 (25)26 (17)15 (19) North America35 (28)6 (14)6 (18)7 (19)41 (26)13 (16) Russia15 (12)10 (23)9 (27)2 (6)24 (15)12 (15) Rest of world56 (46)21 (49)9 (27)18 (50)65 (42)39 (49)Stage of CKD, *n* (%) 20001 (3)01 (1) 3a4 (3)1 (2)1 (3)1 (3)5 (3)2 (3) 3b23 (19)6 (14)3 (9)3 (8)26 (17)9 (11) 458 (47)17 (40)17 (52)15 (42)75 (48)32 (41) 538 (31)19 (44)12 (36)16 (44)50 (32)35 (44)Baseline eGFR (mL/min/1.73 m^2^), mean (SD)21.3 (10.69)19.4 (10.9)17.9 (9.17)18.8 (11.97)20.6 (10. 45)19.2 (11.3)Cardiovascular risk factors, *n* (%)[^c^](#tblfn7){ref-type="table-fn"}*n* = 134*n* = 45*n* = 36*n* = 35*n* = 170*n* = 80 Any29 (22)12 (27)9 (25)6 (17)38 (22)18 (23)  Angina pectoris7 (5)5 (11)03 (9)7 (4)8 (10)  Hyperlipidemia4 (3)2 (4)1 (3)05 (3)2 (3)  Hypertension2 (1)01 (3)03 (2)0  Diabetes002 (6)02 (1)0[^4][^5][^6][^7]

Exposure to study medication
----------------------------

In the rhEPO-naïve group (*n* = 179), 134 participants received a median daprodustat dose of 1 mg at Week 20. Of the rhEPO users (*n* = 71), 36 received a median daprodustat dose of 2 mg at Week 20. Forty-five rhEPO-naïve participants in the control group (rhEPO per investigator discretion) received a median rhEPO dose, standardized to IV epoetin, of 16.5 IU/kg/week at Week 20. The remaining 35 rhEPO users in the control arm received 51.3 IU/kg/week at Week 20 ([Supplementary data, Table S3 in Item S5](#sup1){ref-type="supplementary-material"}). One study participant in the control arm was incorrectly randomized based on prior rhEPO exposure, which accounts for the difference in the safety/drug exposure populations as compared with the randomized population.

Hemoglobin response
-------------------

### Primary analysis

Mean hemoglobin levels at Week 24 were 10.2 g/dL (Cohort 1) and 10.9 g/dL (Cohort 2) in the daprodustat group versus 10.7 g/dL (Cohort 1) and 11.0 g/dL (Cohort 2) in the control group.

This represented an increase from baseline in rhEPO-naïve participants within the daprodustat and control groups for Cohorts 1 and 2 ([Figure 2](#sfy013-F2){ref-type="fig"}). In rhEPO users, hemoglobin at 24 weeks was similar to baseline levels in both daprodustat cohorts and increased in both control cohorts.

![Mean and 95% confidence interval for hemoglobin over time by original (**A**) and amended (**B**) hemoglobin criteria for the rhEPO-naïve group and original (**C**) and amended (**D**) hemoglobin criteria for the rhEPO user group. For Cohort 1, the hemoglobin entry criterion was 8--10 g/dL in the rhEPO-naïve group and 9--10.5 g/dL in rhEPO users, and the hemoglobin target range was 9--10.5 g/dL. For Cohort 2, the hemoglobin entry criterion was 8--11 g/dL in the rhEPO-naïve group and 9--11.5 g/dL in rhEPO users, and the hemoglobin target range was 10--11.5 g/dL. ^a^Baseline values were calculated as the average of measurements at Week-4 and Day 1. BL, baseline; rhEPO, recombinant human erythropoietin.](sfy013f2){#sfy013-F2}

### Secondary analyses

Participants had hemoglobin levels within the target range a median of 82% and 66% of the time and above the target range a median of 0% and 18% of the time between Weeks 12 and 24 in the daprodustat and control groups, respectively ([Table 4](#sfy013-T4){ref-type="table"}). Similar results were seen in a sensitivity analysis performed in all ITT participants where a participant on daprodustat was considered as having hemoglobin below target range once he/she discontinued randomized study medication. However, for participants in the control arm, the hemoglobin measurement was used. If the hemoglobin measurement was missing, we assumed it to be within the hemoglobin target range ([Supplementary data, Table S4 in Item S6](#sup1){ref-type="supplementary-material"}). Seventy-four percent and 59% of participants in the combined daprodustat and combined control groups, respectively, had hemoglobin levels within the target hemoglobin range at Week 24 ([Table 4](#sfy013-T4){ref-type="table"}). Table 4.Hemoglobin time in or above target range (ITT population)[^a^](#tblfn9){ref-type="table-fn"}rhEPO naïverhEPO userTotalDaprodustatControlDaprodustatControlDaprodustatControl(*n* = 112)(*n* = 38)(*n* = 30)(*n* = 32)(*n* = 142)(*n* = 70)Percentage of time spent with hemoglobin in or above target range between Weeks 12 and 24 Within the target range, median[^b^](#tblfn10){ref-type="table-fn"}814794888266 Above the target range median[^b^](#tblfn10){ref-type="table-fn"}03305018Participants with hemoglobin in or above target range at Week 24 Within the target range, *n* (%)78 (74)20 (56)22 (73)19 (63)100 (74)39 (59) Above the target range, *n* (%)23 (22)14 (39)5 (17)9 (30)28 (21)23 (35)[^8][^9][^10]

The changes in hemoglobin were associated with expected changes in red blood cell (RBC) count, hematocrit and absolute reticulocyte count ([Supplementary data, Table S5 in Item S7](#sup1){ref-type="supplementary-material"}).

Three participants on daprodustat (two rhEPO naïve and one rhEPO user) discontinued treatment because of the protocol-defined hemoglobin stopping criteria (hemoglobin \<7.5 g/dL). In the rhEPO-naïve group, six participants (4%) on daprodustat and four participants (5%) in the control group had hemoglobin ≥13 g/dL over the course of the 24-week treatment period. Among the rhEPO users, no participants on daprodustat and one participant (3%) in the control group had hemoglobin ≥13 g/dL.

For simplicity, data for parameters other than hemoglobin are presented for all participants on daprodustat (combined daprodustat group) and all control participants (combined control group).

Erythropoietin and vascular endothelial growth factor levels
------------------------------------------------------------

Plasma EPO levels remained near baseline in the combined daprodustat group and the combined control group (single sample collected during the study visit, predose if scheduled to receive rhEPO) ([Table 5](#sfy013-T5){ref-type="table"}). Table 5.Maximum observed plasma EPO levels (IU/L), plasma VEGF level (ng/L) and change from baseline (ITT population)Combined daprodustatCombined control(*n* = 156)(*n* = 78)Plasma EPO levels (IU/L) Baseline, median (min, max)10.5 (2.5, 100.3)11.4 (2.5, 61.5) Maximum observed EPO level,[^a^](#tblfn12){ref-type="table-fn"} median (min, max)16.1 (4.2, 109.3)19.2 (4.9, 620.6)Plasma VEGF level (ng/L) Baseline,[^b^](#tblfn13){ref-type="table-fn"} median (min, max)65.8 (17.9, 467.9)68.7 (22.9, 1118.5) Maximum observed VEGF,[^c^](#tblfn14){ref-type="table-fn"} median (min, max)105.8 (33.1, 1205.3)94.5 (25.5, 472.7)[^11][^12][^13][^14]

Baseline plasma VEGF values were similar in the combined daprodustat and control groups ([Table 5](#sfy013-T5){ref-type="table"}). VEGF levels were highly variable at all time points, with no clear signal for a change in any treatment group.

Iron use, metabolism and utilization
------------------------------------

During the treatment period, ∼67% of participants received oral iron and ∼10% of participants received IV iron. Participants in the combined daprodustat group received a mean total of 38.1 g of oral elemental iron in the study (0.16 g/day) and participants in the control group received a mean total of 28.0 g (0.13 g/day).

The time course of change in hepcidin is shown in [Figure 3](#sfy013-F3){ref-type="fig"}, and the baseline and change from baseline at Week 24 in measures of iron metabolism are shown in [Supplementary data, Table S6](#sup1){ref-type="supplementary-material"} and [Supplementary data, Figure S2 in Item S8](#sup1){ref-type="supplementary-material"}.

![Geometric mean and 95% confidence interval for hepcidin (µg/L) by visit \[intent-to-treat (ITT) population\].](sfy013f3){#sfy013-F3}

Safety
------

The incidence of any on-therapy AEs was 70% in the combined daprodustat and 68% in the combined control groups ([Table 6](#sfy013-T6){ref-type="table"}). The most frequently reported AEs (≥5%) in the combined daprodustat group were nasopharyngitis, diarrhea and nausea. One participant (\<1%) discontinued study treatment/withdrew from the study due to nausea. Table 6.AEs and frequency of MACE and component endpoints in the combined daprodustat or combined control group (safety population)Combined daprodustatCombined control(*n* = 170)(*n* = 80)AEs occurring in ≥5% of participantsAny event, *n* (%)119 (70)54 (68) Nasopharyngitis20 (12)3 (4) Diarrhea10 (6)6 (8) Nausea8 (5)1 (1) Arthralgia3 (2)4 (5) Pruritus04 (5)Frequency of MACE and component endpointsComposite endpoints, *n* (%) Any MACE[^a^](#tblfn16){ref-type="table-fn"}5 (3)1 (1) Any MACE+[^b^](#tblfn17){ref-type="table-fn"}7 (4)4 (5)Components of composite endpoints,[^c^](#tblfn18){ref-type="table-fn"}*n* (%) All-cause mortality4 (2)1 (1) MI (fatal or nonfatal)1 (\<1)0 Stroke (fatal or nonfatal)00 Hospitalization due to heart failure4 (2)4 (5)[^15][^16][^17][^18]

On-therapy serious AEs (SAEs) were reported in 26 participants (15%) in the combined daprodustat group and 13 participants (16%) in the combined control group. The only SAE reported in \>1% of participants in either treatment group was worsening CKD \[chronic renal failure-MedDRA (Medical Dictionary for Regulatory Activities Terminology)\], which was reported in three participants (2%) in the combined daprodustat group and three participants (4%) in the combined control group. Cardiovascular events, including major adverse cardiovascular events (MACEs) and component endpoints, are summarized in [Table 6](#sfy013-T6){ref-type="table"}. Other preidentified AEs of interest are described in the [Supplementary data, in Item S9](#sup1){ref-type="supplementary-material"}.

Mean (SD) estimated glomerular filtration rate (eGFR) at baseline was 20.6 (10.5) mL/min/1.73 m^2^ in the combined daprodustat group and 19.2 (11.3) mL/min/1.73 m^2^ in the combined control group and did not change by end of study \[−0.2 mL/min/1.73 m^2^ (daprodustat) and −1.0 mL/min/1.73 m^2^ (control)\]. Two participants (1%) on daprodustat and three (4%) on control started dialysis during the study.

Seven participants (4%) on daprodustat and one (1%) in the control group had a blood transfusion during the study. All transfusions occurred during hospitalization for various medical conditions (e.g. sepsis, congestive heart failure exacerbation, non-GI bleeding); in six of seven participants, these occurred at a hemoglobin level \>7.5 g/dL.

LVEF, estimated sPAP and baseline values for other echocardiographic parameters were well balanced in all groups, as were the absolute changes from baseline in on-treatment assessments ([Supplementary data, Table S7 in Item S9](#sup1){ref-type="supplementary-material"}). Six (4%) participants in the combined daprodustat group and four (5%) in the combined control group had LVEF values \<50% at any time during the study. Thirteen (9%) and five (7%) participants in the combined daprodustat and control groups, respectively, had an absolute decrease from baseline in LVEF of \>10%. One (\<1%) participant in the daprodustat group and one (2%) in the control group had an estimated sPAP value that increased \>20 mmHg from baseline at any time during the study.

No adverse trends were noted for clinical laboratory values, electrocardiogram (ECG) values or BP; data for the latter are shown in [Table 7](#sfy013-T7){ref-type="table"}. Furthermore, no changes were seen in visual acuity or intraocular pressure based on the protocol-specified ophthalmology examinations (data not shown). Table 7.Summary of SBP and DBP at Week 24 (safety population)Combined daprodustatControl(*n* = 170)(*n* = 80)SBP (mmHg) Baseline[^a^](#tblfn20){ref-type="table-fn"}  *n*15074  Mean (SD)138.0 (18.5)136.4 (16.5) Change from baseline at Week 24  *n*13766  Mean (SD)−0.4 (16.9)−0.1 (15.3)DBP (mmHg) Baseline[^a^](#tblfn20){ref-type="table-fn"}  *n*15074  Mean (SD)73.0 (12.6)72.1 (10.6) Change from baseline at Week 24  *n*13766  Mean (SD)0.1 (10.5)−0.3 (9.9)[^19][^20]

DISCUSSION
==========

To our knowledge, this is the largest (\>250 participants randomized) and longest (24-week treatment duration) study reported to date of a HIF-PHI in the anemic CKD population not yet on dialysis. Results demonstrate that daprodustat can increase and maintain hemoglobin over 24 weeks within a narrow prespecified target range, most notably evidenced by the percentage of time hemoglobin was in the target range between Weeks 12 and 24 for the rhEPO-naïve participants (81%) and rhEPO users (94%).

Consistent with its mechanism of action and similar to previous reports, \[[@sfy013-B10]\] the effect of daprodustat on hemoglobin occurred with minimal changes in plasma EPO levels that were similar in magnitude to endogenous EPO levels seen during exposure to high altitudes in healthy individuals \[[@sfy013-B17], [@sfy013-B18]\]. If higher EPO levels contribute to the cardiovascular risk associated with rhEPO, \[[@sfy013-B19]\] then daprodustat may provide a safer cardiovascular risk profile.

Daprodustat and control had minimal, if any, effect on *VEGF*, one of the target genes of HIF, consistent with prior observations at similar \[[@sfy013-B10]\] and higher daprodustat doses (10--100 mg) \[[@sfy013-B9]\] as well as with other HIF-PHIs \[[@sfy013-B11]\]. This is also consistent with preclinical work demonstrating that VEGF expression is less sensitive to HIF activation than is EPO expression \[[@sfy013-B20]\].

Measures of iron metabolism changed in a manner consistent with data from previous studies with several PHI agents \[[@sfy013-B9]\]. Hepcidin levels, in general, are suppressed by erythropoiesis, due to increased iron utilization and decreased available stores \[[@sfy013-B21]\]. In the combined daprodustat group, hepcidin levels decreased by 17% while hemoglobin increased, suggesting that this effect could be secondary to erythropoiesis. While the decrease in hepcidin is not as prominent as reported in the earlier dose-ranging studies with daprodustat \[[@sfy013-B9], [@sfy013-B10]\] in this study, lower doses of daprodustat were required to maintain hemoglobin in target ranges. It is conceivable that efficacy of distinct HIF-PHI investigational products differs and that higher daprodustat doses than needed to achieve target hemoglobin are required for increased hepcidin suppression.

Participants were considered iron replete at baseline based on the currently acceptable ferritin and transferrin saturation entry criteria and, although rates of IV iron supplementation in the study were very low (∼10%), 67% of participants received oral iron supplementation, albeit at low doses. Though HIF-PHIs are hypothesized to be iron sparing, this trial, as well as other published CKD trials \[[@sfy013-B11]\], have failed to show a reduction in iron usage; it is likely that trials of longer duration are required to demonstrate a difference.

Treatment with daprodustat for up to 24 weeks demonstrated an AE profile consistent with the comorbidities typical of the CKD population \[[@sfy013-B24]\]. No new safety signals based on the collective safety data were identified for daprodustat.

Seven (4%) participants in the daprodustat group and one (1%) in the control group had a blood transfusion, with the most frequent reason for transfusions cited by investigators being underlying chronic anemia followed by active bleeding (not gastrointestinal). It is possible that transfusions were infrequent in the control group because rhEPO in these participants could be titrated frequently at the investigator's discretion. In the daprodustat group, adjustments were only allowed per the prespecified dose adjustment algorithm every 4 weeks.

Although the study was relatively small and too short in duration to determine MACE frequency and events were not formally adjudicated, the overall rate of MACE in the study was lower than anticipated based on the historical data \[[@sfy013-B2], [@sfy013-B4], [@sfy013-B25]\]. A long-term cardiovascular outcome study is ongoing to conclusively assess these events.

There were no noteworthy changes in the measured echocardiographic parameters for either of the treatment groups. This is in contrast to a 24-week study of daprodustat in patients on hemodialysis where there was an imbalance in the number of participants with an increase from baseline in estimated sPAP of \>20 mmHg in the daprodustat group relative to control due to a number of potential confounders \[[@sfy013-B26]\]. Additionally, dedicated preclinical data (GlaxoSmithKline, unpublished data) and a clinical study in healthy volunteers \[[@sfy013-B27]\] have demonstrated no effect of daprodustat on peak right ventricular pressure or sPAP, respectively, even in the setting of a hypoxic challenge.

No adverse trends were apparent in either treatment group following review of the laboratory data, vital signs, ECGs and ophthalmology examinations. This included no change in BP for the combined daprodustat and control groups. Contrary to the known risk of hypertension associated with rhEPOs and its analogs, \[[@sfy013-B7], [@sfy013-B28]\] the lack of effect on BP in the combined control group could be due to the overall smaller doses of rhEPO in this study and adequate BP control in the rhEPO user group.

There are several limitations in this study that need to be considered. Amending the hemoglobin entry criteria during study conduct necessitated analyzing changes in hemoglobin in the context of different entry criteria and target ranges. This, however, did not affect the interpretation of the hemoglobin time-in-range data where daprodustat was shown to achieve and maintain hemoglobin within a relatively narrow target range. Given the global nature of the study and differing practices in treating anemia, the control group received rhEPO per standard of care as necessary, with the added instruction to treat to the hemoglobin target range. This lack of standardization as to how and when rhEPO was utilized may have contributed to fewer participants with hemoglobin levels within the target range and more above the target range, which may have been consistent with regional standard of care. This was not the case with daprodustat, which was dosed based on a prespecified dose adjustment algorithm. Additionally, the tight eligibility criteria limit the generalizability of the findings, and the degree of noncompletion may complicate interpretation of the results.

Finally, the open-label design could potentially influence how AEs are reported by participants or recorded by study staff. For example, more AEs of nausea were reported in the daprodustat group, which could have been influenced by daprodustat being an investigational medication, or due to an oral route of daprodustat administration. Furthermore, cardiovascular events were not formally adjudicated, even though overall number of MACEs was low. Although this is the largest study to date, the sample size and 6-month duration is not long enough to draw conclusions regarding the long-term safety of daprodustat, particularly regarding cardiovascular risk and cancer.

In conclusion, in this 24-week study in anemic CKD patients, daprodustat effectively achieved target hemoglobin levels in rhEPO-naïve participants and maintained target hemoglobin levels in rhEPO users. Daprodustat was well tolerated with an AE profile consistent with the CKD population. These data support continued development of daprodustat to treat anemia of CKD, regardless of whether patients are rhEPO naïve or already taking rhEPO. This includes an ongoing large-scale cardiovascular outcomes trial (ASCEND-ND) in this population to assess the safety and efficacy of daprodustat (NCT02876835).
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[^1]: rhEPO, recombinant human erythropoietin.

[^2]: Cohort included all countries until Cohort 2 was added; thereafter it applied to the USA only.

[^3]: AE, adverse event; CHr, reticulocyte hemoglobin content; CV, cardiovascular; IV, intravenous; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; PK, pharmacokinetics; RBC, red blood cell; rhEPO, recombinant human erythropoietin; sPAP, systolic pulmonary artery pressure; TIBC, total iron-binding capacity; TSAT, transferrin saturation; VEGF, vascular endothelial growth factor.

[^4]: BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; rhEPO, recombinant human erythropoietin; SC, subcutaneous; SD, standard deviation.

[^5]: Hemoglobin entry criteria for rhEPO-naïve participants were 8--10 g/dL in Cohort 1 and 8--11 g/dL in Cohort 2. Criteria in rhEPO users were 9.0--10.5 g/dL in Cohort 1 and 9.0--11.5 g/dL in Cohort 2.

[^6]: Baseline hemoglobin levels for Cohort 1 and Cohort 2 combined.

[^7]: Safety population.

[^8]: rhEPO, recombinant human erythropoietin.

[^9]: Target range was 9--10.5 g/dL in the original and 10--11.5 g/dL in the amended criteria.

[^10]: The minimum and maximum for all values were 0 and 100, respectively.

[^11]: rhEPO, recombinant human erythropoietin; VEGF, vascular endothelial growth factor.

[^12]: Daprodustat measurements predose and postdose up to 15 h after dosing; control included a single sample during visit (predose if scheduled to receive rhEPO at visit).

[^13]: Baseline is the last predose value.

[^14]: Daprodustat measurements predose and postdose up to 15 h after dosing; control included a single sample during visit (predose if scheduled to receive rhEPO at visit).

[^15]: MACE, major adverse cardiovascular event; MI, myocardial infarction.

[^16]: MACE is defined as a first occurrence of all-cause mortality, a nonfatal MI or a nonfatal stroke.

[^17]: MACE+ is defined as a first occurrence of MACE or hospitalization for heart failure.

[^18]: Includes all events.

[^19]: DBP, diastolic BP; SBP, systolic BP.

[^20]: Baseline is the last predose value.
